Gallery

Sean Sunghun Park, MD, PhD is a Professor and Consultant in Radiation Oncology at Mayo Clinic. He is dually trained in immunology and radiation oncology, with expertise in stereotactic body radiotherapy (SBRT), immuno-radiotherapy combinations, and image-guided radiotherapy. Dr. Park has co-led multiple NCI-funded clinical trials as Co-PI, including phase II studies in oligometastatic prostate cancer, hepatocellular carcinoma, melanoma, and intrahepatic cholangiocarcinoma. His translational research focuses on tumor-reactive T cells, extracellular vesicles, and biomarkers predicting response to SBRT and immunotherapy. He is widely published and nationally recognized for excellence in translational radiation oncology research.

Dr. Andrew Loblaw, BSc MD MSc FRCPC CIP FASCO, is a Radiation Oncologist, Clinician Scientist, and Professor at the University of Toronto, serving as Site Group Co-Lead for Genitourinary Oncology at Sunnybrook Health Sciences Centre. He trained in Radiation Oncology at the University of Toronto while completing a Masters in Clinical Epidemiology through the Clinician Investigator Program. His clinical and research focus is on improving outcomes for men with prostate cancer, image-guided radiotherapy, clinical trial design, and evidence-based guideline development. Dr. Loblaw has authored over 325 peer-reviewed papers, secured over CAD$52M in grants, and is a Fellow of ASCO.

Mutlay Sayan, MD is an Assistant Professor of Radiation Oncology at Harvard Medical School and a practicing radiation oncologist at Dana-Farber/Brigham and Women’s Cancer Center. He earned his BA in Economics and Chemistry and his MD from the University of Vermont, followed by residency and chief residency training in Radiation Oncology. Dr. Sayan is a nationally recognized clinician-scientist with expertise in genitourinary and breast cancers, hypofractionation, proton therapy, and pelvic nodal irradiation. He has authored more than 50 peer-reviewed publications, received multiple research and teaching awards, and serves on national committees for ASTRO, ARS, RSNA-ACR, AUA, and NRG Oncology.

Mohamed Shelan, MD is a Senior Consultant in Radiation Oncology at Bern University Hospital, Switzerland, and holds a Habilitation (Venia Docendi) from the University of Bern. He is board-certified in Radiation Oncology in both Switzerland and Germany. His clinical expertise includes genitourinary cancers, head and neck malignancies, stereotactic radiotherapy, and oligometastatic disease. Dr. Shelan has a strong research focus on advanced radiotherapy technologies, adaptive radiotherapy, and biobank-derived biomarkers. He is Principal Investigator and co-investigator on multiple national and international clinical trials and has authored numerous high-impact publications in leading oncology journals.

Dr. Banu Atalar, M.D., is a Professor of Radiation Oncology at Acibadem MAA University, Istanbul, Türkiye, specializing in Stereotactic Radiosurgery (SRS) and MR-Guided Adaptive SRS. She trained at Cerrahpaşa Medical Faculty and completed a clinical research fellowship at Stanford University. Her clinical focus includes CNS, thoracic, and gastrointestinal tumors. She has authored 72 peer-reviewed publications and is an active member of ASCO, ESTRO, and the Radiosurgery Society. Dr. Atalar has organized national and international oncology courses, chaired multiple congresses, and received prestigious awards including IASLC Mentorship Award and Honorary Fellow of the American College of Radiology.

Dr Zahid Al Mandhari is a Radiation Oncologist graduated from University of Alberta Canada, he was responsible for the digital transformation project at the Sultan Qaboos Comprehensive Cancer Center, He is currently the Head of the HIS committee having introduced many innovative approaches to patient care at this centre. He is an entrepreneur with patented innovative technological solutions in medication error prevention. He is a member of the National Health AI taskforce, a multisectoral taskforce tasked at testing and adopting 4th industrial revolution technologies in the health sector. His main topics of interest are Breast AI, CXR AI, medical automation and screening projects.

Dr. Khalid Alrabiah is a Radiation Oncologist from Riyadh, Saudi Arabia, currently practicing at King Faisal Specialist Hospital & Research Centre (KFSHRC). He completed his medical education at King Saud bin Abdulaziz University for Health Sciences, Riyadh, and his Radiation Oncology residency at McGill University, Montreal, in 2021. Dr. Alrabiah’s clinical interests focus on delivering high-quality, evidence-based cancer care, with particular attention to innovations in radiation therapy and multidisciplinary management. He is actively involved in research and professional development initiatives aimed at improving outcomes for cancer patients and contributes to oncology education and collaborative projects nationally and internationally.

Dr. Ramiz Ahmad Abu-Hijlih is a Consultant Radiation Oncologist at King Hussein Cancer Center (KHCC), Amman, Jordan, and serves as Director of the Radiation Oncology Residency Program. He completed a prestigious clinical fellowship in Genitourinary and Sarcoma Radiation Oncology at Princess Margaret Cancer Centre, University of Toronto. Dr. Abu-Hijlih has extensive expertise in advanced radiotherapy techniques, including IMRT, VMAT, SBRT, and MR-Linac–based adaptive radiotherapy. An active researcher and international journal reviewer, he has authored numerous peer-reviewed publications and received multiple international awards for education, research, and academic leadership in radiation oncology.

Dr. Anoud Zaid Yousef Alnsour, MD is a Consultant Radiation Oncologist at King Hussein Cancer Center (KHCC), Amman, Jordan, where she has been practicing since 2021. She completed her radiation oncology training at KHCC, with additional fellowship training at the Royal Adelaide Hospital, Australia, and observership training at Moffitt Cancer Center, USA. Dr. Alnsour has a strong clinical interest in thoracic and breast malignancies, stereotactic radiotherapy, and advanced treatment techniques. She is actively involved in resident education and has authored multiple peer-reviewed publications. Dr. Alnsour is a frequent national and international speaker in oncology education programs.